A BMJ study examined 55 FDA staff who conducted drug reviews and found 15 of 26 who left the agency later worked for the biopharmaceutical industry. One reviewer who led FDA analysis of AstraZeneca drug reviews joined AstraZeneca as a director and was representing them before her former colleagues within a year. Four of the last five FDA Commissioners left to join pharmaceutical companies or their boards. A Stanford Law paper calls it 'one persistent source of undue influence at the FDA.'